Navigation Links
Physician-scientist urges improved drug regulation to ensure heart safety of non-heart drugs
Date:12/28/2007

Recommendations by NewYork-Presbyterian/Weill Cornell's Dr. Jeffrey Borer Emphasize Need for Better Attention to Cardiovascular Effects, Beginning With Early Studies and Continuing Past Drug Approval

NEW YORK (Dec. 28, 2007) -- Current regulatory policies should be strengthened to ensure acceptable cardiovascular safety of drugs developed primarily for non-cardiovascular medical problems, according to a recent presentation made by Dr. Jeffrey Borer, an authority in cardiovascular medicine and surgery at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City.

His recommendations include earlier testing of all drugs' cardiovascular effects and giving regulatory bodies the authority to mandate continuing evaluation of drug effects, even after approval for marketing.

"The importance of evaluating the cardiovascular safety of new drugs has been highlighted by recent examples of drugs -- anti-arthritis drugs and others -- that were withdrawn from the market when unacceptable cardiovascular risks were discovered after regulatory approval," says Dr. Borer. "It is clear that drugs intended for non-cardiovascular problems must be more fully scrutinized than in the past in order to allow doctors and patients to be assured that risks are well defined and that they do not outweigh the benefits provided by the drugs for the individual patient. The primary strategy to achieve this goal is increasing formal observations in both pre- and post-approval studies."

Specific recommendations include:

  • Cardiovascular safety assessment should be incorporated in drug development beginning with animal studies of drug effects on cardiac physiology/pharmacology, even if the drug is not intended for cardiovascular problems. Similarly, evaluation of cardiovascular effects should begin in the earliest phases of drug testing in patients. The definitions of adverse cardiovascular events like heart attacks and strokes should
    '/>"/>

Contact: Emily Berlanstein
eab2007@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. Physician-scientists seek solutions to reproductive problems related to chromosomal variations
2. Improved e-jet printing provides higher resolution and more versatility
3. In-vitro fertilization improved with 3-D/4-D-guided embryo transfer and new placement target
4. UCR researchers awarded nearly $1.7M to develop improved cowpea varieties
5. Gene regulation, not just genes, is what sets humans apart
6. Evolution is driven by gene regulation
7. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
8. Scientists find clue to mechanisms of gene signaling and regulation
9. Gene regulation in humans is closer than expected to simple organisms
10. The importance of gene regulation for common human disease
11. Einstein researcher receives NIH grant to explore epigenetic regulation of the human genome

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...ers, red deer have been caught in the hunters, sig... more than decorative. They are lethal weapons tha... from The University of York, UK, has been intrigu...alf a century and has become fascinated by the mec...ng collaboration with Tomas Landete-Castillejos at...
(Date:11/26/2009)...phylococcus Aureus ) and other drug-resistant bact...asma prototype devices have been developed to offe...ktails. , Two prototype devices have been develo...n (e.g. hands and feet) in hospitals and public sp...another to shoot bacteria-killing agents into infe...
(Date:11/25/2009)... Cell Death Research Laboratory in the University ... the prestigious Johnson & Johnson Focused Funding...in cell damage in Parkinson,s disease. The award, ...t of innovation and excellence in science, was ann...his month at an event at the Hyatt Regency Hotel i...
Breaking Biology News(10 mins):Tough yet stiff deer antler is materials scientist's dream 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2New Media Led Effort Responds to AIDS Crisis in Black America 50086 1New Media Led Effort Responds to AIDS Crisis in Black America 50086 2New Media Led Effort Responds to AIDS Crisis in Black America 50086 3New Media Led Effort Responds to AIDS Crisis in Black America 50086 4New Media Led Effort Responds to AIDS Crisis in Black America 50086 5New Media Led Effort Responds to AIDS Crisis in Black America 50086 6Abused Kids Face Higher Cancer Risk 50083 1Abused Kids Face Higher Cancer Risk 50083 2U M study finds voice box can be preserved even with the largest cancers 50080 1U M study finds voice box can be preserved even with the largest cancers 50080 2
...gy infrastructure for researching and developing n...e industry hundreds of millions of dollars annuall... the National Institute of Standards and Technolog...T, the studys authors found that over the last two...ted from small-molecule chemicals to large-molecul...
...archers contributed to a national effort to sequen...hat will help advance research in a broad range of... to understanding a variety of human diseases. , ...ectionately as Chlamy, has long fascinated scienti...s that retains characteristics of both. Like green...
...greatly improves the ability to separate global wa...e gas is prepared for use, according to engineers ...yzed the new plastics performance. , Like a spong...astic permits carbon dioxide or other small molecu...t, while impeding natural gas (methane) movement t...
Other Biology News:Biopharmaceutical infrastructure key to lower drug development costs 2'Chlamy' genome holds clues for renewable energy, the environment and human health 2New membrane strips carbon dioxide from natural gas faster and better 2New membrane strips carbon dioxide from natural gas faster and better 3
(Date:11/30/2009)..., Nov. 30 Dr. Jessica Torrente, As...n University Medical Center in Washington, D.C., d...ific Gamma Imaging (BSGI) in clinical practice as ...reast cancer today at the annual meeting of the Ra..."The purpose of the exhibit was to demonstrate how...
(Date:11/30/2009)... PDS, a leader in providing smart and effic...ces Pajama Pathology®, evolutionizing work-fro...;gold standard’ software used by 8 of the To... a ‘cost per slide’ basis. , ...er 30, 2009 -- PDS has announced another evolution...
(Date:11/30/2009)..., LONDON, November 30 ApaTech...named Europe,s fastest growing,Biotech/Pharmaceuti...loitte,2009 Technology Fast 500 for EMEA (Europe, ...nking is based on a companies, five-year revenue g...318% over this period. This,achievement places Apa...
(Date:11/27/2009)...DURHAM, N.C., Nov. 27 Cromoz Inc.,...water-soluble carbon nanotube-based cancer drug de...le carbon nanotubes, which have functional groups ...er drugs, was developed in partnership with the In...bon nanotubes serves as a drug delivery vehicle wi...
Breaking Biology Technology:Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 3ApaTech is Europe's Fastest Growing Lifescience Company 2ApaTech is Europe's Fastest Growing Lifescience Company 3ApaTech is Europe's Fastest Growing Lifescience Company 4North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2
...ED FOR TUESDAY, OCTOBER 28, SAN DIEGO, Oct. 22 N...ced today that the Company will report its third,q...ket closes on Tuesday,October 28, 2008. Neurocrine...iscuss its financial results and provide a Company...0 p.m. Eastern Time (2:00 p.m. Pacific,Time)., Pa...
...Inc.,(Nasdaq: TELK ) announced that its 2008 thir... on Wednesday, November 5, 2008 at 4:30 p.m. Easte...ease earlier that day of the,company,s financial r...008., The conference call will be accessible via ...lephone at 800-398-9367 or 612-332-7517. An,archiv...
...r Systems, Inc., a,medical device company developi... announced today that it has signed an agreement w...ercialize StemCor,s proprietary System,for the har...com/cgi-bin/prnh/20071030/STEMCORSYSTEMSLOGO ), S...spira will manage,the clinical trial program, lead...
Other Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results 2StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists 2StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists 3
...ser-friendly statistical software package for scie...tatistical analysis without being a statistical ex...nd research and SigmaStat suggests the appropriate...lying assumptions and suggests another test if you...
...lus is a chemiluminescent signal enhancing reagent...l obtained with all ECL based Western blot detecti... powerful, innovative proprietary technology. Unli...te enhancers, ChemiLucent™ Plus works throug...
...ts Best: DASGIPs Process Control integrates Proces...es & comprehensive documentation for cultivation p...issolved oxygen, temperature and agitation speed a.... constant or scheduled media flow, are changeabl...
...no acid synthetic peptide whose sequences are deri...this peptide is (amino to carboxy terminus): S(21)... K - K - I - K - Q - D - C(39). This peptide may...s with the polyclonal antibody that reacts with th...
Biology Products: